Value through Innovation29 July 2014

Parkinson's disease (PD) is a degenerative disorder of the central nervous system.

Patients usually notice motor symptoms, like hand tremor (shaking), as their first sign of the disease, which progresses eventually to include shaking of the arms, legs or head. Other motor symptoms that develop over time include stiffness that often results in loss of facial expression and a gradual slowing or loss of motion or "freezing".

Parkinson's disease often includes non-motor symptoms

About 30-40 % of patients also suffer from non-motor symptoms associated with PD, such as depression and sleep disorders. These are often equally important to them and have an enormous impact on their health-related quality of life, as everyday tasks such as dressing, walking, speaking and even writing, become increasingly difficult. PD is therefore considered to be a much more complex syndrome involving motor, as well as non-motor symptoms, and a balanced treatment approach capable of managing these symptoms is required in order to minimise significant functional disability as much as possible.

The clinical benefits of early initiation of dopaminergic therapy on motor, as well as on non-motor symptoms, have become the focus of intensive medical research.

Poor adherence to long term therapies severely compromises the effectiveness of treatment. The once daily dosing has been shown to improve patient compliance in PD.

Products

Mirapex®, Mirapexin®, Sifrol®, Pexola®
Mirapex® extended release, Mirapexin® extended release, Sifrol® Retard, Pexola® extended release
(pramipexole)

Indicated in the symptomatic treatment of idiopathic Parkinson's disease. It may be used as monotherapy or in combination with levodopa. Pramipexole is available as once-daily oral prolonged relase tablets and as immediate release tablets to be taken in equally divided doses three times a day.

Disclaimer

We recognise that the Internet serves a global community. The pharmaceutical industry, however, is subject to country specific regulatory considerations, which affect the information we can provide on our products. In addition the registration status of pharmaceutical products may not be the same in different regions of the world and the approved product labels may also differ according to country specific requirements.

Therefore please check the registration details of this/these product(s) locally in order to get up-to-date information.

Annual Report Website

Annual Report Microsite

Online Activities

  • Mirapex® product website